Abstract
The COVID-19 pandemic, caused by SARS coronavirus 2 (SARS-CoV-2), has resulted in excess morbidity and mortality as well as economic decline. To characterise the systemic host immune response to SARS-CoV-2, we performed single-cell RNA-sequencing coupled with analysis of cell surface proteins, providing molecular profiling of over 800,000 peripheral blood mononuclear cells from a cohort of 130 patients with COVID-19. Our cohort, from three UK centres, spans the spectrum of clinical presentations and disease severities ranging from asymptomatic to critical. Three control groups were included: healthy volunteers, patients suffering from a non-COVID-19 severe respiratory illness and healthy individuals administered with intravenous lipopolysaccharide to model an acute inflammatory response. Full single cell transcriptomes coupled with quantification of 188 cell surface proteins, and T and B lymphocyte antigen receptor repertoires have provided several insights into COVID-19: 1. a new non-classical monocyte state that sequesters platelets and replenishes the alveolar macrophage pool; 2. platelet activation accompanied by early priming towards megakaryopoiesis in immature haematopoietic stem/progenitor cells and expansion of megakaryocyte-primed progenitors; 3. increased clonally expanded CD8+ effector:effector memory T cells, and proliferating CD4+ and CD8+ T cells in patients with more severe disease; and 4. relative increase of IgA plasmablasts in asymptomatic stages that switches to expansion of IgG plasmablasts and plasma cells, accompanied with higher incidence of BCR sharing, as disease severity increases. All data and analysis results are available for interrogation and data mining through an intuitive web portal. Together, these data detail the cellular processes present in peripheral blood during an acute immune response to COVID-19, and serve as a template for multi-omic single cell data integration across multiple centers to rapidly build powerful resources to help combat diseases such as COVID-19.
Competing Interest Statement
SAT has received remunerations for consulting and Scientific Advisory Board work from Genentech, Biogen, Roche and GlaxoSmithKline as well as Foresite Labs over the past three years.
Funding Statement
M.H. is funded by Wellcome (WT107931/Z/15/Z), The Lister Institute for Preventive Medicine and Newcastle NIHR Biomedical Research Centre (BRC); B.G. is funded by Wellcome (206328/Z/17/Z), MRC (MR/S036113/1), and the Aging Biology Foundation. S.A.T. is funded by Wellcome (WT206194), ERC Consolidator and EU MRG-Grammar awards. Z.K.T. and M.R.C. are supported by a Medical Research Council Human Cell Atlas Research Grant (MR/S035842/1). J.C.M. is supported by core funding from Cancer Research UK (C9545/A29580) and from the European Molecular Biology Laboratory (EMBL). M.R.C. is supported by a Versus Arthritis Cure Challenge Research Grant (21777), and an NIHR Research Professorship (RP-2017-08-ST2-002). H.W.K. is supported by Sir Henry Wellcome PostDoctoral fellowship Wellcome Trust (213555/Z/18/Z). K.B.M acknowledges funding from the Chan Zuckerberg Initiative (grant 2017-174169) and from Wellcome (WT211276/Z/18/Z and Sanger core grant WT206194). M.Z.N. acknowledges funding from a UKRI Innovation/Rutherford Fund Fellowship allocated by the MRC and the UK Regenerative Medicine Platform (MR/5005579/1 to M.Z.N.). M.Z.N. and K.B.M. have been funded by the Rosetrees Trust (M944). K.B.W. is funded by University College London, Birkbeck MRC Doctoral Training Programme. J.L.B. acknowledges funding from the MRC and the UK Regenerative Medicine Platform (MR/5005579/1). M.Y. is funded by The Jikei University School of Medicine. K.F.B is funded by an NIHR Clinical Lectureship (CL-2017-01-004). N.M. is supported by a DFG Research Fellowship (ME 5209/1-1). C.J.A.D is funded by Wellcome (211153/Z/18/Z) and acknowledges support from the Barbour Foundation. This work was partly funded by UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patients were consented under the Newcastle Biobank (REC 17/NE/0361, IRAS 233551) study and ethical governance; or (NIHR BioResource REC ref 17/EE/0025, and Genetic variation AND Altered Leukocyte Function in health and disease - GANDALF REC ref 08/H0308/176); or the Living Airway Biobank, administered through UCL Great Ormond Street Institute of Child Health (REC reference: 19/NW/0171, IRAS project ID 261511).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† co-senior authors
Data Availability
The dataset from our study can be explored interactively through a web portal: https://covid19cellatlas.org. The data object, as a h5ad file, can also be downloaded from the portal page. The processed data is available to download from Array Express using accession number E-MTAB-10026.
